Table 2.
Effect of methionine and vitamin B‐complex on hepatic parameters in control and test groups at baseline, 2 and 6 months of antituberculosis drug treatment
| Parameter | Median (IQR) level Control (a) | Median (IQR) level Test (b) | P‐value | |
|---|---|---|---|---|
| Baseline | AST (U/L) | 22.80 (IQR: 15.25–32.10) | 35.00 (IQR: 25.25–49.60) | <0.0001a |
| ALT (U/L) | 9.90 (IQR: 5.7–16.83) | 14.80 (IQR: 7.40–27.10) | 0.008a | |
| ALP (U/L) | 65.60 (IQR: 54.85–90.58) | 82.70 (IQR: 68.80–99.55) | 0.002a | |
| T. Bilirubin (mmol/L) | 4.75 (IQR: 3.35–6.65) | 5.90 (IQR: 4.50–8.35) | 0.01a | |
| Month 2 | AST (U/L) | 56.25 (IQR: 47.20–63.95) | 22.1 (IQR: 15.10–32.80) | <0.001a |
| ALT (U/L) | 74.95 (IQR: 65.38–89.03) | 8.4 (IQR: 4.70–12.30) | <0.001a | |
| ALP (U/L) | 85.4 (IQR: 80.35–102.50) | 64.7 (IQR: 51.70–88.60) | <0.001a | |
| T. Bilirubin (mmol/L) | 8.25 (IQR: 5.48–15.08) | 3.1 (IQR: 2.50–4.00) | <0.001a | |
| Month 6 | AST (U/L) | 30.1 (IQR: 19.60–35.50) | 25.45 (IQR: 16.68–32.73) | 0.276 |
| ALT (U/L) | 17.2 (IQR: 5.30–70.10) | 8.45 (IQR: 4.70–30.75) | 0.183 | |
| ALP (U/L) | 71.35 (IQR: 56.28–83.03) | 68.5 (IQR: 58.30–113.00) | 0.370 | |
| T. Bilirubin (mmol/L) | 4.3 (IQR: 3.25–6.03) | 4.2 (IQR: 3.60–5.30) | 0.910 |
a
Mann Whitney U test (Significant); IQR, Interquartile range.